Related Experiment Video
Updated: Dec 31, 2025
09:11
Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy
Published on: April 9, 2019
22.2K
A Single-center Experience: Does MRI-guided Target Prostate Biopsy Meet Expectations?
Türev Demirtaş1, Gökhan Sönmez2, Şevket T Tombul3
1History of Medicine and Ethics, Erciyes University, Kayseri, TUR.
Cureus
|January 1, 2020
Summary
Target biopsy (TB) aimed for higher cancer detection with fewer cores, but combined biopsy (CB) is now popular. This study found CB detected more clinically significant prostate cancer (sPCa) than TB or standard prostate biopsy (SPB) alone.
Area of Science:
- Urology
- Oncology
- Diagnostic Imaging
Background:
- Target biopsy (TB) was introduced to increase prostate cancer detection rates using fewer cores.
- Combined biopsy (CB), integrating TB and standard prostate biopsy (SPB), has gained popularity despite using more cores.
Purpose of the Study:
- To compare the cancer detection efficacy of CB versus TB and SPB in patients with Prostate Imaging Reporting and Data System (PI-RADS) scores ≥3.
- To evaluate if TB alone achieved its goal of higher cancer detection with fewer cores.
Main Methods:
- Prospective study of 404 patients with PI-RADS ≥3 and serum prostate-specific antigen (PSA) <10 ng/ml.
- All patients underwent both TB (2-5 cores per lesion) and SPB in the same session using fusion ultrasonography.
- CB results were considered the reference standard for histopathological upgrading analysis.
Main Results:
- Combined biopsy (CB) detected clinically significant prostate cancer (sPCa) in 38.4% of patients, significantly higher than TB (30.2%) and SPB (25.5%).
- TB showed the highest sPCa detection rate per core.
- SPB had higher histopathological upgrading rates (10% and 25.7%) compared to TB when CB was the reference.
Conclusions:
- The initial goal of TB to detect more cancers with fewer cores was only partially successful.
- Combined biopsy (CB) demonstrates superior detection rates for clinically significant prostate cancer compared to TB or SPB alone in this patient cohort.
